AZP2006, a New Promising Treatment for Progressive Supranuclear Palsy patients. Phase 2a Study Assessing Tolerability, Safety and Pharmacokinetics. Effect on Biomarkers and Clinical Readouts.

ezeprogind (AZP2006) - AlzProtect

Philippe Verwaerde, PhD1; Cecilia Estrella, PhD1; Aurélien Blondel, PharmD1; Susanna Del Signore, MD1; Noelle Callizot, PhD1,2

Jul 7, 2023